Method of preparing elongated seamless capsules containing biological material

• US 5,418,154 A
• Filed: 12/24/1992
• Issued: 05/23/1995
• Est. Priority Date: 11/17/1987
• Status: Expired due to Term

• Current Assignee: Brown University, Neurotech S.A. (LivaNova Plc)
• Original Assignee: Brown University
• Inventors: Wahlberg, Lars, Aebischer, Patrick, Doherty, Edward J., Tresco, Patrick A., Mills, John F.
• Primary Examiner(s): Naff, David M.
• Application Number:
  US07/997,770
• Time in Patent Office: 880 Days
• Field of Search: 435/178, 435/179, 435/180, 435/182, 435/240.22, 435/240.23, 264/4, 264/417, 425/382 R, 425/382.2, 424/451, 530/817
• US Class Current: 435/182
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61J 3/07 into the form of capsules or similar small containers for oral use
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61K 9/4816 Wall or shell material
• CPC Class Codes: A61K 9/4833 Encapsulating processes; Filling of capsules mechanical aspects A61J3/07
• CPC Class Codes: A61K 9/5089 Processes
• CPC Class Codes: A61M 2210/0687 Skull, cranium
• CPC Class Codes: A61M 2210/0693 Brain, cerebrum
• CPC Class Codes: A61M 2230/005 Parameter used as control input for the apparatus
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: B01J 13/02 Making microcapsules or microballoons for medical preparations A61K9/50
• CPC Class Codes: B01J 13/04 by physical processes, e.g. drying, spraying
• CPC Class Codes: C12N 11/04 entrapped within the carrier, e.g. gel or hollow fibres
• CPC Class Codes: C12N 11/082 obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: C12N 11/087 Acrylic polymers
• CPC Class Codes: C12N 11/098 formed in the presence of the enzymes or microbial cells
• CPC Class Codes: C12N 2533/30 : Synthetic polymers
• CPC Class Codes: C12N 5/0012 : Cell encapsulation
• CPC Class Codes: C12N 5/0614 : Adrenal gland
• CPC Class Codes: C12N 5/0619 : Neurons
• CPC Class Codes: Y10S 530/817 : Entrapped within the carrier, e.g. gel, hollow fibre

Abstract

Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.

Claims

1. A method of integrally forming an elongated seamless capsule having a first end and a second end, the method comprising the sequential steps of:

initiating extrusion of a casting solution through a first outer bore of a multiple annular extrusion port;

subsequently initiating delivery of a coagulant to a second inner bore of the extrusion port to form a coextruded inner core and achieve a smooth first end of a seamless capsule, the coagulant comprising an aqueous solution containing biological material;

terminating delivery of the coagulant; and

subsequently terminating delivery of the casting solution such that essentially no extruded casting solution remains attached to the port to achieve a smooth second end of the seamless capsule, the coagulant with the biological material being contained within the seamless capsule;

wherein the casting solution and the coagulant are selected so that coagulation of the casting solution occurs as the casting solution and the coagulant are extruded through the extrusion port.

2. The method of claim 1 wherein a smooth outer surface is formed on the capsule and autoinitiation is facilitated by extruding the casting solution through a non-porous bore.

3. The method of claim 2 wherein the non-porous bore is a glass bore.

4. The method of claim 1 wherein a step of terminating delivery of the coagulant is followed by a predetermined time delay before termination of the casting solution delivery to form an extended polymeric tether.

5. The method of claim 1 wherein before terminating delivery of the casting solution, delivery of the coagulant is repeatedly sequentially initiated and terminated to form a string of capsules.

6. The method of claim 1 wherein the casting solution is coagulated in an ambient environment external to the casting solution.

7. The method of claim 1 wherein the casting solution is coagulated in an aqueous environment external to the casting solution.

8. The method of claim 1 wherein the coagulant comprises a therapeutic factor.

9. The method of claim 1 wherein the coagulant comprises an aqueous suspension including cells that secrete a biologically active factor.

10. The method of claim 9 wherein the biologically active factor is a neurological factor.

11. The method of claim 10 wherein the neurological factor is a neurotransmitter.

12. The method of claim 9 wherein the biologically active factor is a hormone.

13. The method of claim 12 wherein the hormone is insulin or an active fragment or analog thereof.

14. The method of claim 1 wherein the coagulant comprises an aqueous cell suspension which includes an additive selected from the group consisting of a nutrient medium, an anchorage substrate material, and a combination thereof.

15. The method of claim 1 wherein the casting solution comprises a polymeric solution which includes an additive selected from the group consisting of a surfactant, an anti-inflammatory agent, an antioxidant, an angiogenic factor, and a combination thereof.

16. The method of claim 1 further comprising controlling the viscosity of the casting solution, such that upon coagulation the casting solution will form a capsule having a semipermeable membrane surrounding the coagulant comprising the biological material.

17. The method of claim 1 wherein the casting solution contains solvent and the method further comprises maintaining a pressure differential between the coagulant and the casting solution during co-extrusion to impede solvent diffusion from the casting solution into the coagulant.

18. The method of claim 1 wherein the subsequent initiation of delivery of the coagulant is within a range of between 10 milliseconds and about one second from the initiation of extrusion of the casting solution.

19. The method of claim 1 wherein the subsequent initiation of delivery of the coagulant occurs after a drop of casting solution is removed from the extrusion port and an optimal amount of casting solution remains at the extrusion port to form a smooth first end.

20. An elongated seamless capsule, having a first end and a second end, formed according to the following sequential steps:

initiating extrusion of a casting solution through a first outer bore of a multiple annular extrusion port;

subsequently initiating delivery of a coagulant to a second inner bore of the extrusion port to form a coextruded inner core and achieve a smooth first end of a seamless capsule, the coagulant comprising an aqueous solution containing biological material;

terminating delivery of the coagulant; and

subsequently terminating delivery of the casting solution such that essentially no extruded casting solution remains attached to the port to achieve a smooth second end of the seamless capsule, the coagulant with the biological material being contained within the seamless capsule;

wherein the casting solution and the coagulant are selected so that coagulation of the casting solution occurs as the casting solution and the coagulant are extruded through the extrusion port.

21. The capsule of claim 20 further comprising a tether integral with and extending from the capsule.

22. The capsule of claim 20 wherein the biological material comprises cells which secrete a neurotransmitter.

23. The capsule of claim 20 further comprising a plurality of the fillable chambers, connected to each other by polymeric links.

24. The capsule of claim 20 wherein the capsule comprises at least two component layers of different porosity.

25. The capsule of claim 24 wherein the capsule comprises an inner porous layer having a molecular weight cutoff of about 40-60 kD.

26. The capsule of claim 24 wherein the capsule comprises an outer porous layer having a molecular weight cutoff of about 40-60 kD.

27. The capsule of claim 24 wherein the capsule comprises a porous inner skin layer having a molecular weight cutoff of about 40-60 kD, a porous outer skin layer having a molecular weight cutoff of about 40-60 kD and an intermediate layer of greater porosity.

28. The capsule of claim 20 wherein the capsule further comprises a solid inner core and said biological material is disposed between the inner core and capsule wall.

29. A method of integrally forming an elongated seamless capsule having a first end and a second end, the method comprising the sequential steps of:

initiating extrusion of a casting solution through a first outer bore of a multiple annular extrusion port;

subsequently initiating delivery of a coagulant to a second inner bore of the extrusion port to form a coextruded inner core and achieve a smooth first end of a seamless capsule, the coagulant comprising an aqueous solution containing biological material;

maintaining the flow rate of the coagulant at a faster rate than the flow rate of the casting solution;

terminating delivery of the coagulant; and

subsequently terminating delivery of the casting solution such that essentially no extruded casting solution remains attached to the port to achieve a smooth second end of the seamless capsule, the coagulant with the biological material being contained within the seamless capsule;

wherein the casting solution and the coagulant are selected so that coagulation of the casting solution occurs as the casting solution and the coagulant are extruded through the extrusion port.

30. A method of integrally forming an elongated seamless capsule having a first end and a second end comprising the sequential steps of:

initiating extrusion of a casting solution containing a solvent through a first outer bore of a multiple annular extrusion port;

subsequently initiating delivery of a coagulant to a second inner bore of the extrusion port to form a coextruded inner core and achieve a smooth first end of a seamless capsule, the coagulant comprising an aqueous solution containing biological material;

maintaining a pressure differential between the coagulant and the casting solution during at least a portion of co-extrusion to impede solvent diffusion from the casting solution into the coagulant, and to cause coagulation of the casting solution as the casting solution and the coagulant are extruded through the extrusion port;

terminating delivery of the coagulant; and

subsequently terminating delivery of the casting solution such that essentially no extruded casting solution remains attached to the port to achieve a smooth second end of the seamless capsule, the coagulant with the biological material being contained within the seamless capsule.

31. A method of integrally forming an elongated seamless capsule having a first end and a second end, the method comprising the sequential steps of:

initiating extrusion of a casting solution through a first outer bore of a multiple annular extrusion port, the casting solution having a water-miscible solvent component;

subsequently initiating delivery of an aqueous coagulant, containing biological material, to a second inner bore of the extrusion port to form a coextruded inner core and achieve a smooth first end of a seamless capsule;

terminating delivery of the coagulant; and

subsequently terminating delivery of the casting solution such that essentially no extruded casting solution remains attached to the port to achieve a smooth second end of the seamless capsule, the coagulant with the biological material being contained within the seamless capsule, wherein coagulation of the casting solution occurs as the casting solution and the coagulant are extruded through the extrusion port.